GoodRx Sees Unusually High Options Volume (NASDAQ:GDRX)

GoodRx Holdings, Inc. (NASDAQ:GDRX) was the target of unusually large options trading activity on Thursday. Stock investors bought 10,790 call options on the company. This is an increase of approximately 431% compared to the typical daily volume of 2,032 call options.

Wall Street Analyst Weigh In

A number of brokerages have recently issued reports on GDRX. Deutsche Bank Aktiengesellschaft reiterated a “hold” rating and set a $6.00 target price on shares of GoodRx in a research report on Monday, August 11th. Weiss Ratings reiterated a “hold (c-)” rating on shares of GoodRx in a research report on Saturday, September 27th. Finally, Raymond James Financial lowered GoodRx from a “strong-buy” rating to an “outperform” rating in a research report on Friday, August 8th. Five equities research analysts have rated the stock with a Buy rating and seven have assigned a Hold rating to the company’s stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Hold” and an average price target of $5.80.

GoodRx Trading Up 0.9%

Shares of GDRX stock opened at $4.53 on Friday. The stock’s fifty day moving average is $4.25 and its two-hundred day moving average is $4.39. The company has a debt-to-equity ratio of 0.75, a quick ratio of 4.21 and a current ratio of 4.21. The firm has a market capitalization of $1.57 billion, a P/E ratio of 45.30, a PEG ratio of 1.96 and a beta of 1.23. GoodRx has a fifty-two week low of $3.31 and a fifty-two week high of $7.20.

GoodRx (NASDAQ:GDRX) last announced its quarterly earnings data on Wednesday, August 6th. The company reported $0.09 earnings per share for the quarter, missing analysts’ consensus estimates of $0.10 by ($0.01). The firm had revenue of $203.07 million during the quarter, compared to analysts’ expectations of $205.72 million. GoodRx had a net margin of 4.33% and a return on equity of 8.86%. The company’s revenue for the quarter was up 1.2% on a year-over-year basis. During the same quarter in the previous year, the business posted $0.08 EPS. Research analysts expect that GoodRx will post 0.13 earnings per share for the current fiscal year.

Insider Activity at GoodRx

In other news, major shareholder Equity Vii L.P. Spectrum sold 16,016 shares of the firm’s stock in a transaction that occurred on Friday, September 5th. The shares were sold at an average price of $4.05, for a total transaction of $64,864.80. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. 4.53% of the stock is owned by insiders.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in GDRX. Deutsche Bank AG purchased a new position in GoodRx in the 4th quarter valued at $137,000. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC lifted its holdings in GoodRx by 70.4% in the 4th quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 149,945 shares of the company’s stock valued at $697,000 after purchasing an additional 61,924 shares in the last quarter. Assenagon Asset Management S.A. lifted its holdings in GoodRx by 12.2% in the 1st quarter. Assenagon Asset Management S.A. now owns 362,713 shares of the company’s stock valued at $1,600,000 after purchasing an additional 39,337 shares in the last quarter. CWA Asset Management Group LLC purchased a new position in shares of GoodRx during the 1st quarter worth $292,000. Finally, Teacher Retirement System of Texas purchased a new position in shares of GoodRx during the 1st quarter worth $218,000. Hedge funds and other institutional investors own 63.77% of the company’s stock.

GoodRx Company Profile

GoodRx Holdings, Inc, together with its subsidiaries, offers information and tools that enable consumers to compare prices and save on their prescription drug purchases in the United States. The company operates a price comparison platform that provides consumers with curated, geographically relevant prescription pricing, and access to negotiated prices.